A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Balint, Catherine; Bekaii-Saab, Tanios; Campbell, Angela; Chen, Helen; Culler, Kristy; Dai, Zunyan; Dancey, Janet; Eng, Charis; Grever, Michael; Heerema, Nyla; Lee, Ruey Min; Markowitz, Joseph; O'Neil, Bert; Papp, Audrey; Prescott, Nichole; Sadee, Wolfgang; Villalona-Calero, Miguel; Wei, Lai; Zalupski, Mark

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Authors: Catherine Balint
Tanios Bekaii-Saab
Angela Campbell
Helen Chen
Kristy Culler
Zunyan Dai
Janet Dancey
Charis Eng
Michael Grever
Nyla Heerema
Ruey Min Lee
Joseph Markowitz
Bert O'Neil
Audrey Papp
Nichole Prescott
Wolfgang Sadee
Miguel Villalona-Calero
Lai Wei
Mark Zalupski
Publication date: 1 January 2009
Publisher
Doi

Abstract

Hepatocellular carcinoma (HCC) is on the rise worldwide. HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of EGFR and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:bn999d73c

Last time updated on 24/11/2020